Skip to Content
Merck
All Photos(1)

Documents

V900185

Sigma-Aldrich

Acetylsalicylic acid

Vetec, reagent grade, ≥99%

Synonym(s):

2-Acetoxybenzoic acid, O-Acetylsalicylic acid, ASA, Aspirin

Sign Into View Organizational & Contract Pricing


About This Item

Linear Formula:
2-(CH3CO2)C6H4CO2H
CAS Number:
Molecular Weight:
180.16
Beilstein:
779271
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:

grade

reagent grade

product line

Vetec

Assay

≥99%

form

powder

mp

134-136 °C (lit.)

solubility

ethanol: 50 mg/mL, clear, colorless

SMILES string

CC(=O)Oc1ccccc1C(O)=O

InChI

1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)

InChI key

BSYNRYMUTXBXSQ-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

Biochem/physiol Actions

Blocks the production of prostaglandins by inhibiting cyclooxygenase (prostaglandin H synthase), with greater selectivity toward the COX-1 isoform. The antithrombotic effect is due to the inhibition of COX-1 in platelets that blocks thromboxane production and platelet aggregation. Chemopreventive against colorectal and other solid tumors.

Legal Information

Vetec is a trademark of Merck KGaA, Darmstadt, Germany

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 1

Flash Point(F)

482.0 °F - closed cup

Flash Point(C)

250 °C - closed cup


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Connie N Hess et al.
Journal of the American College of Cardiology, 66(7), 777-787 (2015-08-14)
Bleeding limits anticoagulant treatment in patients with acute coronary syndromes (ACS). We investigated whether background concomitant antiplatelet therapy influences the effects of apixaban after ACS. This study examined high-risk ACS patients who were treated with aspirin or aspirin plus clopidogrel
Fabrizio D'Ascenzo et al.
The American journal of cardiology, 115(9), 1185-1193 (2015-03-24)
The optimal antiaggregant therapy after coronary stenting in patients receiving oral anticoagulants (OACs) is currently debated. MEDLINE and Cochrane Library were searched for studies reporting outcomes of patients who underwent PCI and who were on triple therapy (TT) or dual-antiplatelet
Andrew O Maree et al.
Journal of the American College of Cardiology, 46(7), 1258-1263 (2005-10-04)
We investigated whether use of low-dose enteric-coated (EC) aspirin for secondary prevention of cardiovascular events has sufficient bioavailability to achieve complete platelet cyclooxygenase (COX) inhibition in all individuals. Aspirin reduces cardiovascular morbidity and mortality in patients with pre-existing vascular disease;
Laurent Arnaud et al.
Autoimmunity reviews, 13(3), 281-291 (2013-11-06)
We performed a meta-analysis to determine whether aspirin has a significant protective effect on risk of first thrombosis among patients with antiphospholipid antibodies (aPL+). Observational and interventional studies identified from the Medline, Embase and Cochrane databases were selected if they
Ahmed Kayssi et al.
Journal of vascular surgery, 60(1), 106-110 (2014-03-25)
Acute limb ischemia (ALI) in pediatric patients is rare but may lead to limb loss and life-long complications. This study reviewed the experience of a Canadian tertiary pediatric center with the medical and operative management of ALI. The medical records of

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service